Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Drug Manufacturers - Specialty & Generic

Healthcare
$21.88 -0.90%

-$0.15 today

Market cap
$7.62B
Beta
1.32
P/E (TTM)
43.4
EPS (TTM)
$0.37
52W Low $7.67High $16.61

Volume 1.91M

Average 1.75M

AMRX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Amneal Pharmaceuticals, Inc.NASDAQ: AMRX

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $10.39M rose 25.6% year over year, ahead of the -10.2% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +0.1% a year.

Context

  • Stock-based compensation amounted to 1.1% of revenue in FY2025, unchanged from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +25.6% holds above the trailing-twelve-month pace of -10.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$10.39M— QoQ
Last fiscal yearDec 2025
$31.95M+15.1% YoY
LTMJun 2026
$26.81M-10.2% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.6%——
1 year+15.1%——
3-year CAGR+0.1%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
31.95M USD
Year-over-year change
+15.1%

Stock-Based Compensation vs competitors

How AMRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.2% is the 9th highest of 11, against a peer median of +11.9%.
  • Stock-based compensation amounts to 0.9% of revenue for AMRX, versus a peer median of 1.3%.
AMRX Competitors
Stock-Based Compensation for AMRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VTRSViatris Inc.LTM Jun 2026$172.3M USD+9.7%+15.1%1.2%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$168M USD+24.4%+8.2%1.0%
BHCBausch Health Companies Inc.LTM Jun 2026$149M USD+12.9%+19.7%1.4%
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹117M INR-72.7%—0.0%
INDVIndivior Pharmaceuticals IncLTM Jun 2026$32M USD+23.1%+17.6%2.4%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$29.06M USD-7.1%+37.5%3.1%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$28.16M USD+10.9%+15.2%3.9%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$26.81M USD-10.2%+0.1%0.9%
PRGOPerrigo Company plcLTM Jun 2026$21.2M USD-17.8%—0.5%
EBSEmergent BioSolutions Inc.LTM Mar 2026$16.6M USD+22.1%-28.9%2.5%
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026$440.95K USD+48.3%-3.0%1.1%
Peer median (excluding AMRX) —+11.9%+15.2%1.3%

Competitors are the stored peer set for AMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income10.62M(254.79M)(48.72M)(73.88M)72.06M
Depreciation & Amortization233.41M240.18M229.4M236.19M223.57M
Deferred Income Tax00000
Stock-Based Compensation031.85M26.82M27.77M31.95M
Change in Working Capital(133.59M)(59.95M)(47.19M)(4.07M)(204.52M)
Accounts Receivables(16.31M)(79.07M)125.8M(162.16M)(120.57M)
Inventory(49.02M)(102.4M)(126.18M)(130.53M)(87.03M)
Accounts Payables(43.93M)109.57M(94.45M)235.14M21.32M
Other Working Capital(24.34M)11.95M47.64M53.48M(18.23M)
Other Non-Cash Items131.38M107.81M185.26M109.08M216.93M
Operating Cash Flow241.82M65.1M345.58M295.1M339.99M
Capital Expenditures(47.73M)(90.6M)(69.19M)(74.99M)(70.06M)
Acquisitions (Net)(141.54M)(84.71M)011.99M0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(3.21M)(40.8M)(22.39M)(14.65M)(42.2M)
Investing Cash Flow(194.18M)(174.31M)(69.19M)(63M)(112.26M)
Debt Repayment(79.18M)(38.27M)22.65M(185.12M)26.27M
Common Stock Issued853K0001.96M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(59.8M)(68.35M)(235.23M)(26.67M)(59.76M)
Financing Cash Flow(138.12M)(106.62M)(212.57M)(211.79M)(31.53M)
Effect of Forex Changes102K(5.68M)65K(999K)(1.68M)
Net Change in Cash(90.38M)(221.51M)63.88M19.31M194.52M
Free Cash Flow194.09M(25.5M)276.39M220.11M269.93M

Amneal Pharmaceuticals, Inc.

NASDAQ:AMRX

Intrinsic Alpha fair value

Locked

Current Price

$21.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.